Cells stop dividing when a few telomeres (protective chromosome ends) that produce the most TERRA RNA become critically short: Corrado Caslini’s theory
Cells stop dividing when a few telomeres (protective chromosome ends) that produce the most TERRA RNA become critically short: Corrado Caslini’s theory
On November 11, Biogerontology published a review by independent researcher Corrado Caslini. He links the cessation of cell division to the state of chromatin (DNA packaged with proteins) at telomeres, building on his own work from 2009.
Telomeres shorten with each cell division. When they become too short, the cell permanently stops dividing, a state called cellular senescence. In 2002, Titia de Lange’s laboratory showed that human cells with excess TRF2, a protein that protects chromosome ends, had faster telomere shortening but stopped dividing at the usual time, when their telomeres were shorter: 4 thousand base pairs rather than 7. The authors concluded that a change in telomere protection causes cells to stop dividing.
In the review manuscript, Caslini writes that cells “both ‘count divisions’ and interpret the state of the telomere, which depends on its length and chromatin configuration.” In a 2009 study, Caslini and colleagues showed that the enzyme MLL binds to telomeres and adds a mark to DNA-packaging proteins that makes genes accessible for transcription. In aging human cell cultures, MLL declined at shortening telomeres, and levels of TERRA, an RNA transcribed from DNA near the telomere, fell. When MLL levels were reduced in young cells, a DNA damage signal appeared at telomeres, and p53, a protein that stops damaged cells from dividing, triggered cellular senescence.
Caslini proposes that when a telomere becomes critically short, shelterin, the protective protein complex that includes TRF2, reorganizes the surrounding chromatin. This reduces access for MLL and RNA polymerase to the DNA regions where TERRA transcription begins.
He identifies the end of chromosome 20 (20q) as one of the main sources of TERRA. In cells from osteosarcoma, a bone tumor, deleting a region of 20q reduced total TERRA levels by 20–50 %. Carol Greider’s group showed in mice that the shortest telomeres limit cell viability and found in 147 people that 20q is, on average, among the shortest telomeres. In Caslini’s model, chromosome ends that are both critically short and major sources of TERRA, such as 20q, are the most likely to drive cells into senescence. He calls these ends “nodal.”
The model proposes that TERRA levels initially rise as telomeres shorten: MLL and p53 increase its production, and loops formed by RNA and DNA probably help repair the telomere. When nodal ends, the main sources of TERRA, become critically short, TERRA levels fall throughout the cell. In osteosarcoma cells, TERRA recruits a protein complex to telomeres that deposits marks promoting chromatin compaction. According to the model, without TERRA, chromatin becomes less compact, DNA damage signaling persists, and p53 triggers cellular senescence.
Caslini proposes testing the role of nodal ends by editing individual telomeres. To test how sustained TERRA production affects senescence, he proposes targeting fusion proteins, in which MLL is joined to another protein, to these ends. In his own 2023 study, leukemia cell lines carrying these proteins had higher TERRA levels than other leukemia cell lines, regardless of telomere length.
On November 3, EMBO Reports published a review by four authors, including Claus Azzalin, first author of the 2007 paper that described TERRA. Their model proposes that unresolved telomere damage keeps TERRA levels high, driving cells toward senescence and death. Caslini’s model instead predicts that TERRA levels fall before cells stop dividing.
- https://doi.org/10.1007/s10522-026-10542-w
- https://pubmed.ncbi.nlm.nih.gov/11923537/
- https://www.preprints.org/manuscript/202606.2047/v2
- https://pubmed.ncbi.nlm.nih.gov/19528237/
- https://pubmed.ncbi.nlm.nih.gov/29670078/
- https://pubmed.ncbi.nlm.nih.gov/11595186/
- https://pubmed.ncbi.nlm.nih.gov/38603523/
- https://pubmed.ncbi.nlm.nih.gov/36979904/
- https://doi.org/10.1038/s44319-026-00978-z
- https://pubmed.ncbi.nlm.nih.gov/17916692/